Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Argan (AGX) Cash & Equivalents (2016 - 2026)

Argan's Cash & Equivalents history spans 17 years, with the latest figure at $339.5 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 133.7% to $339.5 million in Q1 2026 year-over-year; TTM through Jan 2026 was $339.5 million, a 133.7% increase, with the full-year FY2026 number at $339.5 million, up 133.7% from a year prior.
  • Cash & Equivalents hit $339.5 million in Q1 2026 for Argan, up from $306.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for AGX hit a ceiling of $350.5 million in Q1 2022 and a floor of $136.1 million in Q4 2022.
  • Historically, Cash & Equivalents has averaged $209.0 million across 5 years, with a median of $192.3 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: plummeted 68.25% in 2022 and later surged 133.7% in 2026.
  • Tracing AGX's Cash & Equivalents over 5 years: stood at $136.1 million in 2022, then soared by 36.38% to $185.6 million in 2023, then dropped by 5.51% to $175.3 million in 2024, then surged by 74.68% to $306.3 million in 2025, then grew by 10.84% to $339.5 million in 2026.
  • Business Quant data shows Cash & Equivalents for AGX at $339.5 million in Q1 2026, $306.3 million in Q4 2025, and $177.8 million in Q3 2025.